Forced ‘Omicron Boosters’ Are Already On Biden’s Agenda

The discovery of a new COVID variant could be a boost to pharmaceutical giants which have already made big money from vaccines and are now moving with fast speed to create another “jab” to protect against the so-called omicron strain, the newest in a possibly endless string of mutations that could lead the industry for many years to come.

Americans who were happily watching the Thanksgiving holiday were served up with a triple serving of media hysteria over the fresh variant which threatens to upend a country that has already been hit by onerous restrictions, increasing inflation, job losses and shortages. However, as reported by Big Pharma’s spokespersons, a vaccine might be ready to go in the next 100 days.

In a comment emailed to Fox Business, Pfizer said that the vaccine makers were “staying vigilant” and “constantly having surveillance efforts centered on watching for emerging variants that possibly escape the protection of the vaccine.”

The company also said that, “As always, we will keep following the science as we look at the best approaches to guard people against COVID-19,” Pfizer said. “In the event that a vaccine-escape virus variant shows up, Pfizer and BioNTech believe they can produce a tailor-created vaccine against this variant in around 100 days, subject to regulatory approval.”

Fox Business also got a separate comment from a BioNTech spokesperson.

“The variant differs greatly from previously seen variants as it has new mutations located within the spike protein. We expect more information from the lab tests in two weeks at the most recent. These data will give more information about whether B.1.1.529 could be an escape virus variant that may need an adjustment to our vaccine if the variant goes global,” the network said.

“Pfizer and BioNTech have worked to be able to change the mRNA in six weeks and create initial supply within 100 days in the possibility of an escape variant. To this end, the companies have started clinical trials using variant-specific vaccines (delta and alpha) to collect tolerability and safety data that can be given to officials as part of their blueprint studies for a possible variant-specific vaccine,” the spokesman said.

Author: Scott Dowdy